Establishment of a human B-cell tumor in athymic mice.

Abstract

Human B-cell tumors have been established in athymic, BALB/c mice using the EBV-positive Burkitt lymphoma cell line Namalwa. One-hundred-one of 104 animals (97%) developed tumors 10-14 days following s.c. injection of a mixture of 20 x 10(6) Namalwa and 5 X 10(6) irradiated human fibrosarcoma (HT-1080) cells. Tumors developed at the site of injection and reached approximately 300 mm2 (product of cross-sectional diameters) after 21 days; no metastases were found. Histological analysis showed that tumors consisted solely of lymphoid cells. Immunofluorescence assays demonstrated that while 85% of the tumor cells retained reactivity with the monoclonal B-cell antibody BA-1, 96% retained reactivity with antibody BA-2 and 43% with BA-3. A similar reactivity profile was observed with cultured Namalwa cells. Tumors were passaged serially 10 times without significant change in BA-1, BA-2, or BA-3 reactivity. Indirect immunofluorescence demonstrated that antibody BA-2 reached tumor cells within 2 h following i.p. injection; antigen modulation was not observed. These results demonstrate the suitability of this B-cell model for testing the in vivo efficacy and stability of anti-B-cell immunoconjugates.

• Authors: J E Leonard, D E Johnson, R B Felsen, L E Tanney, I Royston, R O Dillman
• Journal: Cancer research (Cancer Res) Vol. 47 Issue 11 Pg. 2899-902 (Jun 01 1987) ISSN: 0008-5472 [Print] United States
• PMID: 3105870 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antibodies, Monoclonal
• Antigens, Differentiation, B-Lymphocyte
• Antigens, Surface

Topics

• Animals
• Antibodies, Monoclonal
• Antigens, Differentiation, B-Lymphocyte
• Antigens, Surface (analysis)
• B-Lymphocytes (immunology, pathology)
• Burkitt Lymphoma (pathology)
• Cell Line
• Humans
• Mice
• Mice, Nude
• Neoplasm Transplantation
• Neoplasms, Experimental (pathology)